A Phase 3 interventional study of glepaglutide and Placebo in Short Bowel Syndrome, sponsored by Zealand Pharma. Completed at 29 sites in 9 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by Zealand Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Short Bowel Syndrome with a site in United States — 11 open to participants now, 15 under way, 4 of them phase 3. Short Bowel Syndrome · United States.
Among the 80 studies in Short Bowel Syndrome with a site in United States, this one is the 7th largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2018, is one of 20 in phase 3, and was the 54th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →11 of the 80 studies in Short Bowel Syndrome with a site in United States are open now. Recruiting first, the newest first:
VectivBio AG · Sites in United States, Argentina, Australia and 19 more countries
Ages 18+
Zealand Pharma · Sites in United States, Austria, Belgium and 11 more countries
Ages 18–90
Eclipse Regenesis, Inc. · Sites in United States
Ages 3 mo–65 yrs
Children's Hospital of Philadelphia · Sites in United States
Ages 4 mo–18 yrs · Healthy volunteers
Hanmi Pharmaceutical Company Limited · Sites in United States, Belgium, Denmark and 5 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 23 · Phase 4 7
First in 1996; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 23 across the 66 interventional studies, 143 across the 10 observational. Of the 52 that completed or were terminated, 29 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 80 have an industry lead sponsor. The 10 most frequent:
Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
Zealand Pharma has 7 studies filed under Short Bowel Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Short Bowel Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05018286Phase 3VectivBio AGOpen-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. | 2027-10-30 |
| NCT06240065University of Texas Southwestern Medical CenterSuccessful Fiber Food Introduction in Short Bowel Syndrome | 2027-04 |
| NCT03530852Boston Children's HospitalA 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB | 2027-06-30 |
| NCT05432648Children's Hospital of PhiladelphiaFiber Food Introduction in Pediatric Short Bowel Syndrome | 2027-08-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 80 studies in Short Bowel Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome.
Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide subcutaneous (SC) injections in patients with short bowel syndrome (SBS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: Glepaglutide
Drug: glepaglutide
Intervention: Glepaglutide
Drug: glepaglutide · Drug: Placebo
Intervention: Placebo
Drug: Placebo
Glucagon-Like Peptide-2 (GLP-2) analog
Also known as: ZP1848
Placebo for glepaglutide
Change in Weekly Parenteral Support (PS) Volume
Change in weekly PS volume from baseline to Week 24. Baseline actual weekly PS volume was defined as the actual PS volume derived from a valid 7-day period prior to visit 1 (Day 1), i.e. during the stabilization phase. The actual weekly PS volume at Weeks 1, 2, 4, 8, 12, 16, 20, and 24 was derived as the actual weekly PS volume received during the valid 7-day period prior to the visit. The source for the derivation was the PS volumes recorded by the patients in the eDiary.
Time frame: 24 weeks
Clinical Response in PS Volume
Clinical response, defined as at least 20% reduction in actual weekly PS volume from baseline to both Weeks 20 and 24.
Time frame: 20 and 24 weeks
Days Off PS
Achieving 1 or more days per week off PS
Time frame: 24 weeks
Clinical Response in PS Volume
Reduction of at least 20 percent in PS volume from baseline to both 12 and 24 weeks.
Time frame: 12 and 24 weeks
Weaned Off PS
Reduction in weekly PS volume of 100 percent (weaned off)
Time frame: 24 weeks
Energy Content
Change in weekly energy content of PS from baseline
Time frame: 24 weeks
Days on PS
Change in number of days on PS per week from baseline
Time frame: 24 weeks
Change in PS Volume Per Week
Achieving reduction of at least 40 percent in PS volume from baseline to both 20 and 24 weeks
Time frame: 20 and 24 weeks
Patient Global Impression of Change Scale (PGIC)
Patient Global Impression of Change scale (PGIC) improvement at Weeks 4, 12, 20, and 24 PGIC improvement was defined as responding "Very Much Improved" or "Much Improved" on a 7-point Likert Scale. Improvement between each glepaglutide treatment regimen compared to placebo was tested by week, using the CMH test adjusted for the stratification factor. Improvement between each glepaglutide treatment regimen versus placebo was tested using collapsed categories of Improvement, No Change, and Worsening, where Improvement is defined as a response of "Very Much Improved" or "Much Improved" or "Minimally Improved", and No Change is defined as the response of "No Change", and Worsening is defined as a response of "Minimally Worse" or "Much Worse" or "Very Much Worse". Improvement using collapsed categories between each glepaglutide treatment regimen compared to placebo was tested by week using a Mantel-Haenszel chi-squared test for ordered categories.
Time frame: 24 weeks
Safety - Adverse Events
Incidence and type of Adverse Events over an average of 28 weeks (24 weeks treatment + 4 weeks follow up)
Time frame: 28 weeks
Number of Patients With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG)
Number of patients with clinically significant changes in ECG will be reported. Monitored ECG parameters included heart rate (beats/min), PR interval (ms), PR interval Aggregate (ms), QRS duration aggregate (ms), QT interval aggregate (ms), QTcF interval aggregate (ms), and RR interval (ms), as well as the overall interpretation of each subject's ECG recorded as Normal, Abnormal Not Clinically Significant, or Abnormal Clinically Significant.
Time frame: 28 weeks
Safety - Changes in Blood Pressure From Baseline
Changes in blood pressure are reported at Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24 The data collected data are of seated diastolic and systolic blood pressure (mmHg). During treatment phase visits, vital signs were collected before investigational product injection.
Time frame: Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24
Safety - Changes in Body Temperature From Baseline
Changes in body temperature are reported The body temperature (ºC or ºF) was measured according to the site's usual procedure. During treatment phase visits, vital signs were collected before investigational product injection.
Time frame: 28 weeks
Immunogenicity - Occurrence of Anti-drug Antibodies
Occurrence of antibodies against glepaglutide The occurrence of glepaglutide-binding antibodies (ADA), M2 binding antibodies (M2 BAb), glepaglutide neutralizing antibodies (NAb) and GLP-2 cross-reacting antibodies (GLP-2 CR) was tested.
Time frame: 28 weeks
This trial was conducted in (number of sites that randomized patients in parenthesis) Belgium (1), Denmark (2), France (2), Germany (5), the Netherlands (1), Poland (3), Canada (3), the US (7), and the UK (5).
| Milestone | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| Started | 35 | 35 | 36 |
| Completed | 31 | 35 | 36 |
| Not completed | 4 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 |
| Withdrew: Icf withdrawal | 2 | 0 | 0 |
Change in weekly PS volume from baseline to Week 24. Baseline actual weekly PS volume was defined as the actual PS volume derived from a valid 7-day period prior to visit 1 (Day 1), i.e. during the stabilization phase. The actual weekly PS volume at Weeks 1, 2, 4, 8, 12, 16, 20, and 24 was derived as the actual weekly PS volume received during the valid 7-day period prior to the visit. The source for the derivation was the PS volumes recorded by the patients in the eDiary.
| L/week | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| Change in Weekly Parenteral Support (PS) Volume | -5.13 (-6.24 to -4.02) | -3.76 (-4.96 to -2.56) | -2.85 (-3.93 to -1.77) |
Clinical response, defined as at least 20% reduction in actual weekly PS volume from baseline to both Weeks 20 and 24.
| Participants | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| Clinical Response in PS Volume | 23 | 16 | 14 |
Achieving 1 or more days per week off PS
| Participants | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| Days Off PS | 18 | 12 | 7 |
Reduction of at least 20 percent in PS volume from baseline to both 12 and 24 weeks.
| Participants | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| Clinical Response in PS Volume | 19 | 15 | 13 |
Reduction in weekly PS volume of 100 percent (weaned off)
| Participants | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| Weaned Off PS | 5 | 4 | 0 |
Change in weekly energy content of PS from baseline
| kJ/week | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| Energy Content | -7360.6 (-48521 to 130351) | -3085.9 (-56550 to 1423) | -734.2 (-46307 to 1670) |
Change in number of days on PS per week from baseline
| days/week | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| Days on PS | -1.00 (-5.0 to 0.0) | 0.00 (-7.0 to 1.0) | 0.00 (-4.0 to 0.0) |
Achieving reduction of at least 40 percent in PS volume from baseline to both 20 and 24 weeks
| Participants | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| Change in PS Volume Per Week | 15 | 10 | 8 |
Patient Global Impression of Change scale (PGIC) improvement at Weeks 4, 12, 20, and 24 PGIC improvement was defined as responding "Very Much Improved" or "Much Improved" on a 7-point Likert Scale. Improvement between each glepaglutide treatment regimen compared to placebo was tested by week, using the CMH test adjusted for the stratification factor. Improvement between each glepaglutide treatment regimen versus placebo was tested using collapsed categories of Improvement, No Change, and Worsening, where Improvement is defined as a response of "Very Much Improved" or "Much Improved" or "Minimally Improved", and No Change is defined as the response of "No Change", and Worsening is defined as a response of "Minimally Worse" or "Much Worse" or "Very Much Worse". Improvement using collapsed categories between each glepaglutide treatment regimen compared to placebo was tested by week using a Mantel-Haenszel chi-squared test for ordered categories.
| participants | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| PGIC improved | 22 | 27 | 13 |
| PGIC much/very much improved | 17 | 11 | 2 |
Incidence and type of Adverse Events over an average of 28 weeks (24 weeks treatment + 4 weeks follow up)
| Participants | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| All AEs | 33 | 33 | 27 |
| Serious adverse events | 9 | 10 | 7 |
| AE Severity: Severe | 10 | 5 | 2 |
| AE Severity: Moderate | 15 | 18 | 14 |
| AE Severity: Mild | 28 | 32 | 24 |
| Relationship: Related | 27 | 26 | 14 |
| Relationship: Unlikely related | 18 | 16 | 9 |
| Relationship: Not related | 26 | 26 | 23 |
| AEs leading to trial withdrarwal | 2 | 0 | 0 |
| AEs with action taken drug withdrawn | 2 | 1 | 0 |
| AEs with action taken drug interrupted | 3 | 0 | 3 |
| Outcome: Recovered/resolved | 32 | 30 | 25 |
| Outcome: Recovering/resolving | 7 | 9 | 5 |
| Outcome: Recovered/resolved with sequelae | 1 | 1 | 0 |
| Outcome: Not recovered/not resolved | 17 | 14 | 9 |
| Outcome: Fatal | 0 | 0 | 0 |
| Outcome: Unknown | 1 | 0 | 0 |
| Outcome: MIssing | 0 | 0 | 0 |
Number of patients with clinically significant changes in ECG will be reported. Monitored ECG parameters included heart rate (beats/min), PR interval (ms), PR interval Aggregate (ms), QRS duration aggregate (ms), QT interval aggregate (ms), QTcF interval aggregate (ms), and RR interval (ms), as well as the overall interpretation of each subject's ECG recorded as Normal, Abnormal Not Clinically Significant, or Abnormal Clinically Significant.
| Participants | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| Number of Patients With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) | 0 | 0 | 0 |
Changes in blood pressure are reported at Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24 The data collected data are of seated diastolic and systolic blood pressure (mmHg). During treatment phase visits, vital signs were collected before investigational product injection.
| mmHg | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| Week 1 Systolic blood pressure | -2.8 (-7.6 to 2.0) | 0.3 (-4.1 to 4.7) | -4.5 (-8.2 to -0.7) |
| Week 2 Systolic blood pressure | 1.0 (-3.2 to 5.1) | -0.1 (-4.6 to 4.4) | -2.7 (-6.4 to 1.0) |
| Week 4 Systolic blood pressure | -1.7 (-6.5 to 3.1) | -0.2 (-3.9 to 3.4) | -0.3 (-4.6 to 3.9) |
| Week 8 Systolic blood pressure | 0.3 (-5.4 to 6.0) | -1.5 (-5.9 to 2.9) | -2.5 (-6.9 to 1.8) |
| Week 12 Systolic blood pressure | -4.4 (-9.6 to 0.8) | 3.3 (-1.0 to 7.6) | -0.4 (-5.0 to 4.1) |
| Week 16 Systolic blood pressure | 0.1 (-5.6 to 5.8) | 0.4 (-4.7 to 5.5) | -1.1 (-6.3 to 4.1) |
| Week 20 Systolic blood pressure | 1.3 (-5.8 to 8.3) | 1.2 (-3.6 to 6.0) | -1.0 (-6.2 to 4.3) |
| Week 24 Systolic blood pressure | -1.0 (-6.2 to 4.1) | -1.1 (-5.6 to 3.4) | -5.9 (-11.0 to -0.8) |
| Week 1 Diastolic blood pressure | 0.4 (-2.3 to 3.0) | 0.5 (-2.6 to 3.5) | -2.0 (-4.6 to 0.6) |
| Week 2 Diastolic blood pressure | 2.5 (0.2 to 4.7) | -0.7 (-3.1 to 1.7) | -1.7 (-5.0 to 1.6) |
| Week 4 Diastolic blood pressure | 0.0 (-2.8 to 2.8) | -0.2 (-2.5 to 2.8) | -1.5 (-4.6 to 1.6) |
| Week 8 Diastolic blood pressure | -0.5 (-3.3 to 2.3) | 1.9 (-1.3 to 5.0) | -0.6 (-3.3 to 2.2) |
| Week 12 Diastolic blood pressure | -2.8 (-6.7 to 1.2) | 2.0 (-1.0 to 5.1) | 0.9 (-1.8 to 3.6) |
| Week 20 Diastolic blood pressure | 2.1 (-1.5 to 5.7) | -0.7 (-3.9 to 2.4) | 0.4 (-3.3 to 4.1) |
| Week 24 Diastolic blood pressure | 2.2 (-1.6 to 5.9) | 0.0 (-2.7 to 2.7) | -0.9 (-3.8 to 2.1) |
Changes in body temperature are reported The body temperature (ºC or ºF) was measured according to the site's usual procedure. During treatment phase visits, vital signs were collected before investigational product injection.
| degree C | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| Week 1 | 0.0 (-0.1 to 0.2) | -0.0 (-0.2 to 0.1) | 0.1 (-0.0 to 0.2) |
| Week 2 | 0.1 (-0.0 to 0.2) | -0.0 (-0.2 to 0.1) | 0.0 (-0.1 to 0.1) |
| Week 4 | -0.1 (-0.2 to 0.1) | -0.0 (-0.2 to 0.1) | 0.1 (-0.1 to 0.2) |
| Week 8 | 0.0 (-0.1 to 0.2) | 0.1 (-0.0 to 0.2) | -0.1 (-0.2 to 0.1) |
| Week 12 | -0.0 (-0.2 to 0.1) | -0.0 (-0.1 to 0.1) | 0.1 (-0.1 to 0.2) |
| Week 16 | -0.0 (-0.1 to 0.1) | -0.0 (-0.1 to 0.1) | 0.0 (-0.1 to 0.1) |
| Week 20 | 0.1 (-0.1 to 0.2) | 0.0 (-0.1 to 0.1) | 0.1 (-0.1 to 0.2) |
| Week 24 | -0.0 (-0.1 to 0.1) | 0.1 (-0.0 to 0.2) | 0.1 (0.0 to 0.2) |
Occurrence of antibodies against glepaglutide The occurrence of glepaglutide-binding antibodies (ADA), M2 binding antibodies (M2 BAb), glepaglutide neutralizing antibodies (NAb) and GLP-2 cross-reacting antibodies (GLP-2 CR) was tested.
| Participants | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| ADA (Treatment-induced) | 30 | 31 | 0 |
| M2 BAb (Treatment-induced) | 28 | 29 | 0 |
| NAb M2 (Treatment-induced) | 10 | 14 | 0 |
| GLP-2 CR (Treatment-induced) | 6 | 11 | 0 |
Collected over All AEs, whether serious or non-serious, were to be reported from the time a signed and dated Informed Consent Form (ICF) was obtained until the end of the post-treatment follow-up period on average 28 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Glepaglutide SC Injections Twice Weekly | 0/35 (0%) | 9/35 (25.7%) | 30/35 (85.7%) |
| Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | 0/35 (0%) | 10/35 (28.6%) | 31/35 (88.6%) |
| Placebo SC Injections Twice Weekly | 0/36 (0%) | 7/36 (19.4%) | 25/36 (69.4%) |
| Event | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| Stoma site haemorrhageInjury, poisoning and procedural complications | 1/17 | 0/20 | 0/21 |
| PyrexiaGeneral disorders | 1/35 | 2/35 | 0/36 |
| Device related sepsisInfections and infestations | 2/35 | 2/35 | 1/36 |
| Vascular device infectionInfections and infestations | 0/35 | 2/35 | 2/36 |
| Acetabulum fractureInjury, poisoning and procedural complications | 1/35 | 0/35 | 0/36 |
| Peripheral arterial occlusive diseaseVascular disorders | 0/35 | 1/35 | 0/36 |
| DizzinessNervous system disorders | 1/35 | 0/35 | 0/36 |
| Blood loss anaemiaBlood and lymphatic system disorders | 1/35 | 0/35 | 0/36 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/35 | 0/35 | 0/36 |
| Catheter site necrosisGeneral disorders | 0/35 | 1/35 | 0/36 |
| Event | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly |
|---|---|---|---|
| Injection site reactionGeneral disorders | 9/35 | 15/35 | 1/36 |
| Stoma site oedemaInjury, poisoning and procedural complications | 4/17 | 2/20 | 0/21 |
| NauseaGastrointestinal disorders | 7/35 | 3/35 | 1/36 |
| Injection site erythemaGeneral disorders | 5/35 | 6/35 | 1/36 |
| Abdominal painGastrointestinal disorders | 5/35 | 6/35 | 2/36 |
| VomitingGastrointestinal disorders | 3/35 | 6/35 | 0/36 |
| HeadacheNervous system disorders | 4/35 | 3/35 | 3/36 |
| PyrexiaGeneral disorders | 4/35 | 1/35 | 1/36 |
| FatigueGeneral disorders | 4/35 | 4/35 | 0/36 |
| Injection site painGeneral disorders | 4/35 | 3/35 | 0/36 |
| Age, Categorical(Participants) | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 23 | 28 | 30 | 81 |
| >=65 years | 12 | 7 | 6 | 25 |
| Age, Continuous(years) | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly | Total |
|---|---|---|---|---|
| Mean | 56.9 ± 13.4 | 54.0 ± 12.0 | 55.0 ± 11.8 | 55.0 ± 12.4 |
| Sex: Female, Male(Participants) | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly | Total |
|---|---|---|---|---|
| Female | 19 | 18 | 20 | 57 |
| Male | 16 | 17 | 16 | 49 |
| Ethnicity (NIH/OMB)(Participants) | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 30 | 33 | 32 | 95 |
| Unknown or Not Reported | 5 | 1 | 4 | 10 |
| Race (NIH/OMB)(Participants) | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 1 | 3 |
| White | 28 | 31 | 30 | 89 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 3 | 5 | 13 |
| Region of Enrollment(participants) | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly | Total |
|---|---|---|---|---|
| Canada | 1 | 0 | 3 | 4 |
| Netherlands | 2 | 0 | 2 | 4 |
| Belgium | 3 | 4 | 3 | 10 |
| United States | 4 | 13 | 6 | 23 |
| Denmark | 5 | 2 | 1 | 8 |
| Poland | 8 | 7 | 12 | 27 |
| United Kingdom | 4 | 4 | 1 | 9 |
| France | 5 | 1 | 3 | 9 |
| Germany | 3 | 4 | 5 | 12 |
| BMI(kg/m^2) | Glepaglutide SC Injections Twice Weekly | Glepaglutide SC Injections Once Weekly and Placebo Once Weekly | Placebo SC Injections Twice Weekly | Total |
|---|---|---|---|---|
| Mean | 23.57 ± 3.35 | 22.72 ± 3.21 | 23.54 ± 3.57 | 23.28 ± 3.37 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in Jul 2022, 45 months.
Results were first posted in Oct 2024, 2 years 2 months after primary completion. A results delay was requested in May 2023.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 45 months is above that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glepaglutide